Lifeboat Foundation

New AI supercomputer from Graphcore will have 500 trillion parameters, (5x that of human brain) and compute at a speed of 10 exaflops per second (10x that of human brain) for a cost of $120 million USD. New AI powered exoskeleton uses machine learning to help patients walk. AI detects diabetes and prediabetes using machine learning to identify ECG signals indicative of the disease. AI identifies cancerous lesions in IBD patients.

AI News Timestamps:
0:00 New AI Supercomputer To Beat Human Brain.
3:06 AI Powered Exoskeleton.
4:35 AI Predicts Diabetes.
6:55 AI Detects Cancerous Lesions For IBD

Continue reading “New Fastest AI Supercomputer To Surpass Human Brain By 5X Size & 10X Speed | AI Powered Exoskeleton” »

Understanding the busy networks inside our cells can help researchers develop new cancer treatments and prevent dangerous fungal infections.

With the help of the Canadian Light Source (CLS) at the University of Saskatchewan, a research team led by John Allingham from Queen’s University and Hernando Sosa from the Albert Einstein College of Medicine has shed light on a protein that regulates the intricate microscopic networks that give cells their shape and helps ship important molecules to diverse locations.

Using the CMCF beamline at the CLS and the cryo-EM facility at the Simons Electron Microscopy Center (SEMC) at the New York Structural Biology Center, the team found the missing pieces of an important puzzle.

New research published in Experimental Neurology provides some initial evidence that the psychedelic substance known as LSD has nootropic properties. The study found that LSD increased markers of neuroplasticity in human brain organoids, increased novelty preference in rats, and improved memory performance in humans.

When combined with psychotherapy, psychedelic drugs have shown promise in the treatment of psychiatric conditions such as depression, PTSD, and addiction. But the cellular and molecular mechanisms involved in the therapeutic effects of psychedelics remains unclear.

Some research has indicated that psychedelic substances produce positive impacts, in part, because they promote neurogenesis and neuroplasticity. The authors of the new study were interested in better understanding whether the neuroplasticity induced by psychedelics could be harnessed to enhance learning and memory.

About a month before giving birth, Kelly Spill said she noticed something wasn’t right. When using the bathroom, she reported “seeing blood,” and the problem persisted…

Researchers at the Hebrew University of Jerusalem have discovered a new family of molecules that enable cells to repair damaged components, making it possible for those tissues to retain proper function. The efficacy of the molecules was demonstrated on a model organism – the C. elegans roundworm. The research team examined the effect of various therapies on longevity and quality of life, and successfully showed they can protect the worm and human cells from damage.

The researchers, led by Professors Einav Gross and Shmuel Ben-Sasson, have founded a company called Vitalunga to advance the research and translate it into therapeutics.

Longevity. Technology: A major factor in aging tissues is the reduced effectiveness of our cell’s quality-control mechanism, which leads to the accumulation of defective mitochondria – the cellular ‘power plants’ responsible for energy production. Mitochondria can be compared to tiny electric batteries that help cells function properly. Although these ‘batteries’ wear out constantly, our cells have a sophisticated mechanism called mitophagy that removes defective mitochondria and replaces them with new ones. However, this mechanism declines with age, leading to cell dysfunction and deterioration in tissue activity, and is implicated in many age-related diseases, such as Alzheimer’s disease, Parkinson’s disease, heart failure and sarcopenia.

An Israeli company has launched a clinical trial to determine if its innovative microbiome-based therapeutic could increase the responsiveness of some cancer patients to immunotherapy.

The microbiome is gut bacteria – trillions of microorganisms that live in the intestinal tract and play a role in digestion, immunity and many other aspects of health.

Rehovot-based Biomica, a subsidiary of Evogene, dosed its first patients in a Phase I clinical trial at Rambam Health Care Campus last month with a new drug – BMC128 – that is expected to help patients who do not respond to immunotherapy. Specifically, the company hopes the trial will demonstrate the safety, tolerability and preliminary clinical effectiveness of its BMC128 microbiome-based immuno-oncology drug candidate in combination with immune checkpoint inhibitor (ICI) immunotherapy.

It’s a question that keeps some scientists awake at night: Do spiders sleep?

A surgical tool currently in clinical trials will slice fake flesh in space — providing groundbreaking new tech for space-based medical emergencies.